We rank companies based on fund manager, research analyst and news sentiment
ZVSA

ZyVersa Therapeutics, Inc. Common Stock
ZVSA

$0.71
5.33%
 

About: ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Employees: 7

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

12% more capital invested

Capital invested by funds: $162K [Q3] → $181K (+$19.7K) [Q4]

8.9% more ownership

Funds ownership: 3.4% [Q3] → 12.29% (+8.9%) [Q4]

50% less funds holding

Funds holding: 12 [Q3] → 6 (-6) [Q4]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

67% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 9

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$12
1,590%
upside
Avg. target
$16
2,154%
upside
High target
$24
3,280%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Ed Arce
1,590%upside
$12
Buy
Reiterated
26 Mar 2024
HC Wainwright & Co.
Ed Arce
1,590%upside
$12
Buy
Maintained
12 Mar 2024
HC Wainwright & Co.
Ed Arce
3,280%upside
$24
Buy
Reiterated
29 Feb 2024

Financial journalist opinion

Based on 3 articles about ZVSA published over the past 30 days